May 13, 2021: Disparities in U=U awareness; sexual satisfaction trends among PLWH; PrEP use among cis women; HCV epidemiology in trans women.
“This Information Will Be Useful in the Future”: How a Tuberculosis Toolkit Became a COVID-19 Timeline
A newly launched chronology traces the unfolding pandemic and the consequences of economic and political decisions around the world.
In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.
Feb. 18, 2021: Insomnia rates among PLWH; trends in multimorbidity diagnosis; viral load control loss in the modern HIV treatment era; acceptability of HIV self-test dissemination methods.
Feb. 4, 2021: STI rates among PrEP users; how Medicaid expansion affects HIV testing and PrEP rates; utilizing mental health care providers in PrEP uptake; adapting HIV care in the COVID era.
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.
Hostilities against migrants and indigenous people are also threats to their health.